Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 4/20 | 0.54 |
| ▸ | ACHE | P22303 | 7/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14355120 | 0.83 | METAP1 (0.57) | METAP1ACHEHTR2CDRD3HTR1A | |
| SCHEMBL20359102 | 0.78 | METAP1 (0.58) | METAP1ACHEHTR2CDRD3HTR1A | |
| SCHEMBL9324677 | 0.78 | METAP1 (0.63) | METAP1ACHEHTR2CDRD3HTR1A | |
| SCHEMBL11770524 | 0.78 | METAP1 (0.58) | METAP1ACHEHTR2CDRD3HTR1A | |
| SCHEMBL6271181 | 0.77 | METAP1 (0.71) | METAP1ACHEHTR2CDRD3HTR1A | |
| SCHEMBL6270614 | 0.77 | METAP1 (0.71) | METAP1ACHEHTR2CDRD3HTR1A | |
| SCHEMBL1853465 | 0.75 | ACHE (0.63) | METAP1ACHEHTR2CDRD3HTR1A | |
| SCHEMBL677676 | 0.74 | ACHE (0.58) | METAP1ACHEHTR2CDRD3HTR1A | |
| SCHEMBL21064364 | 0.74 | METAP1 (0.58) | METAP1ACHEHTR2CDRD3HTR1A | |
| SCHEMBL29122994 | 0.74 | METAP1 (0.58) | METAP1ACHEHTR2CDRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2221296-B1 | FUSED INDANE COMPOUND | ASTELLAS PHARMA INC (JP) | 2012-09-05 | — | — | EP | disclosed |
| CN-101878201-B | Fused indane compound | ASTELLAS PHARMA INC | 2012-09-05 | — | — | CN | disclosed |
| US-8211907-B2 | Fused indane compound | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| CN-101878201-A | Fused indane compound | ASTELLAS PHARMA INC | 2010-11-03 | — | — | CN | disclosed |
| US-20100267695-A1 | FUSED INDANE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2221296-A1 | FUSED INDANE COMPOUND | Astellas Pharma Inc. (JP) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267695-A1 | FUSED INDANE COMPOUND | GRIN2A, GRIN2C, GRIN1 | METAP1 1317/4885ACHE 63/4885HTR2C 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.